Morgan Stanley Maintains Overweight on Zentalis Pharma, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Zentalis Pharma (NASDAQ:ZNTL) but has lowered the price target from $55 to $38.
November 07, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target, Morgan Stanley maintains an Overweight rating on Zentalis Pharma, indicating a positive outlook.
The lowered price target might initially seem negative, but the maintained Overweight rating indicates that Morgan Stanley still sees potential in Zentalis Pharma. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100